Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -45

Moderna stock falls 6% in premarket: here's why

Analyst downgrade Financial outlook AI-generated analysis

πŸ“‰ Moderna stock dropped nearly 6% in premarket trading following Citigroup's downgrade from 'Hold' to 'Sell' and a price target increase to $80.

πŸ’° Citi analyst Geoff Meacham stated that even with a 100% success rate for the intismeran oncology program, the stock supports only a ~$100 valuation.

πŸ“Š The company's roughly $80 billion market cap is comparable to Regeneron despite Moderna having significantly lower expected revenue and earnings.

πŸš€ Shares have rallied 223% since August 19 after positive late-stage trial results for the personalized cancer vaccine candidate intismeran autogene.

πŸ”¬ The lead oncology program combined with Merck's Keytruda met trial goals in more than 1,100 patients with higher-risk or advanced melanoma.

⚠️ Citi estimates Moderna would need to generate about $26 billion in annual oncology sales to justify a share price near $200.

πŸ“ˆ The current valuation reflects aggressive sales expectations and probability-of-success assumptions that the bank considers unrealistic.

πŸ₯ While melanoma is viewed as a favorable setting for demonstrating treatment potential, other applications like renal and lung cancers present different biological challenges.

πŸ“‰ Citigroup's new $80 price target implies roughly 61% downside from Tuesday's closing price of $203.46.

πŸ‘₯ Analyst sentiment remains mixed with 15 of 24 analysts rating the stock as a buy, while three hold underperform ratings.

Bullish Signals
  • Moderna shares have rallied 223% since August 19 following positive late-stage trial results for its personalized cancer vaccine candidate intismeran autogene.
  • The lead oncology program, when combined with Merck's Keytruda, met trial goals in more than 1,100 patients with higher-risk or advanced melanoma.
Risk Factors
  • Citigroup downgraded Moderna from 'Hold' to 'Sell' and raised its price target to $80, citing concerns that the current valuation is difficult to justify.
  • Citi estimates that even assigning a 100% probability of success to intismeran oncology programs would only support a price target of about $100 per share.
  • The firm stated that Moderna would need to generate about $26 billion in annual oncology sales to justify a share price near $200, which is almost seven times its current model.
Full Analysis
Moderna (MRNA) shares fell nearly 6% in premarket trading after Citigroup downgraded the biotechnology company from 'Hold' to 'Sell' and raised its price target to $80 from $60. The downgrade stems from concerns that Moderna's current valuation is difficult to justify given its lower expected revenue and earnings compared to peers like Regeneron, despite having a similar market capitalization of roughly $80 billion. Citi analyst Geoff Meacham noted that even assuming a 100% probability of success for Moderna's lead oncology program, intismeran autogene, the stock would only support a price target of approximately $100. To justify the current trading level near $203, the firm estimates Moderna would need to generate about $26 billion in annual oncology sales, which is roughly seven times its current model projections. The aggressive valuation reflects high expectations for intismeran's performance following positive late-stage trial results released on August 19. These trials showed the personalized cancer vaccine combined with Merck's Keytruda met goals in over 1,100 patients with advanced melanoma, driving a rally that saw shares rise from around $62 to an intraday high of $208 before the recent decline.